Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Vascular Permeability Factor, Etc.); Or Binds Serum Protein, Plasma Protein, Fibrin, Or Enzyme Patents (Class 424/158.1)
  • Patent number: 10783349
    Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 22, 2020
    Assignee: AXOGEN CORPORATION
    Inventor: Curt Deister
  • Patent number: 10781252
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: September 22, 2020
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia Patricia Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Patent number: 10745475
    Abstract: The invention relates to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of inflammatory disorders such as rheumatoid arthritis according to specific dosing regimen. The invention relates also to neutralizing antibodies of GM-CSF and compositions comprising the same for use in the treatment of pain, e.g. pain experienced in inflammatory disorders such as rheumatoid arthritis, according to specific dosage regimen.
    Type: Grant
    Filed: September 1, 2014
    Date of Patent: August 18, 2020
    Assignee: TAKEDA GMBH
    Inventors: Thomas Wagner, Malin Carlsson, Margit Staum Kaltoft
  • Patent number: 10736900
    Abstract: The invention relates to a combination of a FGFR inhibitor and an IGF1R inhibitor. The combination is for use in the treatment of a proliferative disorder, in particular for the treatment of cancer. The FGFR inhibitor and the IGFR inhibitor can be administered simultaneously, separately or sequentially. The invention further relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a combination according to the invention.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Eleonora Jovcheva, Timothy Pietro Suren Perera
  • Patent number: 10739352
    Abstract: A method of diagnosis or prediction of infection of a mammalian wound, said method comprising the step of detecting the presence of a cytokine selected from the group comprising procalcitonin, amino procalcitonin (N-ProCT), eotaxin, granulocyte macrophage colony stimulating factor (GM-CSF), interleukins IB monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1 alpha (MIP-1a), regulated upon activation normal T expressed and secreted (RANTES) in fluid taken from the wound. Also claimed is the device for use in the method.
    Type: Grant
    Filed: November 20, 2008
    Date of Patent: August 11, 2020
    Assignee: CONVATEC TECHNOLOGIES INC.
    Inventors: Philip Godfrey Bowler, Samantha Alison Jones, Sarah Anne Welsby
  • Patent number: 10729769
    Abstract: The present invention relates to novel liquid pharmaceutical compositions of adalimumab, which include adalimumab or a biosimilar thereof, an acetate buffering agent/system such as sodium acetate/acetic acid, and a sugar stabiliser such as trehalose. Such a combination of components furnishes formulations having a stability (e.g. on storage and when exposed to stress) which is comparable to or an improvement upon those known in the art, and with fewer ingredients. Such advances will help adalimumab treatments to become more widely available at lower cost, and prolong the viability of pre-loaded delivery devices (e.g. pre-filled syringes) to reduce unnecessary waste of the drug.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: August 4, 2020
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Gianluca Rinaldi, Silvia Fratarcangeli, Alessandra Del Rio
  • Patent number: 10696738
    Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: June 30, 2020
    Assignee: Glaxon Group Limited
    Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
  • Patent number: 10683349
    Abstract: The present disclosure relates to antibodies and proteins comprising an antigen-binding portion thereof that specifically bind to the pro-inflammatory cytokine IL-17 A. The disclosure more specifically relates to specific antibodies and proteins that are IL-17 A antagonists (inhibit the activities of IL-17 A and IL-17 AF) and are capable of inhibiting IL-17 A induced cytokine production in in vitro assays, and having an inhibitory effect in an antigen-induced arthritis model in vivo. The disclosure further relates to compositions and methods of use for said antibodies and proteins to treat pathological disorders that can be treated by inhibiting IL-17A or IL 17AF mediated activity, such as rheumatoid arthritis, psoriasis, systemic lupus erythematosus (SLE), lupus nephritis, chronic obstructive pulmonary disease, asthma or cystic fibrosis or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 16, 2020
    Assignee: NOVARTIS AG
    Inventors: Franco E. Di Padova, Thomas Huber, Jean-Michel Rene Rondeau
  • Patent number: 10683368
    Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein a) the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and b) the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and c) the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region polypeptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprisi
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: June 16, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ekkehard Moessner, Tilman Schlothauer
  • Patent number: 10656153
    Abstract: Devices, solutions and method capable of quantifying a clinically significant amount of antibodies within a plasma sample obtained from an individual by quantifying binding between antibodies within the sample and microbial proteins are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 19, 2020
    Assignee: PZM DIAGNOSTICS, LLC
    Inventor: Peilin Zhang
  • Patent number: 10640558
    Abstract: The present invention provides antibodies that bind to human interleukin-25 (IL-25) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human IL-25 with high affinity. In certain embodiments, the invention includes antibodies that bind human IL-25 and block IL-25-mediated cell signaling. The antibodies of the invention may be fully human, non-naturally occurring antibodies. The antibodies of the invention are useful for the treatment of various disorders associated with IL-25 activity or expression, including asthma, allergy, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, atopic dermatitis (AD), and Eosinophilic Granulomatosis with Polyangiitis (EGPA), also know as Churg-Strauss Syndrome.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: May 5, 2020
    Assignee: REGENERON PHAMACEUTICALS, INC.
    Inventors: Jamie M. Orengo, Jeanne Allinne
  • Patent number: 10570199
    Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: February 25, 2020
    Assignee: KM Biologics Co., Ltd.
    Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
  • Patent number: 10526402
    Abstract: The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: January 7, 2020
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D'Andrea, Kalindi Parmar, Haojian Zhang
  • Patent number: 10500252
    Abstract: The present invention provides a method of treating an intracellular infection in a subject wherein the method comprising administering to the subject an IAP antagonist. In certain embodiments the IAP antagonist is a Smac mimetic.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 10, 2019
    Assignee: WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH
    Inventors: Marc Pellegrini, Gregor Klaus-Peter Ebert, Colin Glenn Begley
  • Patent number: 10478497
    Abstract: The present invention concerns combinations of inecalcitol with an anti-CD38 agent such as daratumumab, MOR 202 or isatuximab for the treatment of cancer, such as hematological malignancies by increasing or inducing the expression of CD-38 by inecalcitol.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: November 19, 2019
    Assignee: HYBRIGENICS S.A.
    Inventors: Susan Benjamin, Cécile Planquette, Rémi Delansorne
  • Patent number: 10472425
    Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: November 12, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Scott M. Walsh, Daniel B. Dix
  • Patent number: 10464998
    Abstract: This invention relates to methods and compositions for treating fibrosis, by administering compositions comprising anti-LPS immunoglobulin enriched colostrum preparations. In particular, the invention relates to methods and compositions for the treatment of liver fibrosis and/or lung fibrosis. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed and claimed.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: November 5, 2019
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LIMITED
    Inventors: Yaron Ilan, Meir Mizrahi
  • Patent number: 10441215
    Abstract: One embodiment includes an image acquisition circuit that accesses a pre-treatment and a post-treatment image of a region of tissue demonstrating non-small cell lung cancer (NSCLC), a segmentation and registration circuit that annotates the tumor represented in the images, and that registers the pre-treatment image with the post-treatment image; a feature extraction circuit that selects a set of pre-treatment and a set of post-treatment quantitative vessel tortuosity (QVT) features from the registered image; a delta-QVT circuit that generates a set of delta-QVT features by computing a difference between the set of post-treatment QVT features and the set of pre-treatment QVT features; and a classification circuit that generates a probability that the region of tissue will respond to immunotherapy based on the difference, and that classifies the region of tissue as a responder or non-responder. Embodiments may generate an immunotherapy treatment plan based on the classification.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: October 15, 2019
    Assignee: Case Western Reserve University
    Inventors: Anant Madabhushi, Yuanqi Xie, Vamsidhar Velcheti
  • Patent number: 10426797
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., United States of America as Represented by the Secretary, The Dept. of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Patent number: 10408847
    Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: September 10, 2019
    Assignee: SomaLogic, Inc.
    Inventors: Urs Ochsner, David G. Sterling, Nebojsa Janjic
  • Patent number: 10400035
    Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 3, 2019
    Assignees: MedImmune, LLC, University of Helsinki
    Inventors: Kari Alitalo, Simo Syrjala, Karl Lemstrom, Ching Ching Leow, Ronald Herbst, Jane Connor
  • Patent number: 10400036
    Abstract: The present invention provides compositions and methods which involve specifically antagonizing GDF8 and Activin A. In certain embodiments, compositions are provided which comprise a GDF8-specific binding protein and an Activin A-specific binding protein. For example, the invention includes compositions comprising an anti-GDF8 antibody and an anti-Activin A antibody. In other embodiments, antigen-binding molecules are provided which comprise a GDF8-specific binding domain and an Activin A-specific binding domain. For example, the invention includes bispecific antibodies that bind GDF8 and Activin A. The compositions of the present invention are useful for the treatment of diseases and conditions characterized by reduced muscle mass or strength, as well as other conditions which are treatable by antagonizing GDF8 and/or Activin A activity.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 3, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Trevor Stitt, Esther Latres
  • Patent number: 10385127
    Abstract: The present invention relates to compositions and methods for the inhibition of EPO. The invention provides antibodies and antigen binding fragments thereof that bind to EPO and are able to inhibit EPO-dependent cell proliferation and/or EPO-dependent cell signaling.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: August 20, 2019
    Assignee: NOVARTIS AG
    Inventors: Joy Ghosh, Mark Anthony Rutz, Kathrin Ulrike Tissot-Daguette, Igor Splawski, Michael Roguska
  • Patent number: 10376582
    Abstract: The invention provides buffered formulations of adalimumab. The formulations comprise a buffer comprising an acetate salt, mannitol, glacial acetic acid, sodium chloride, and polysorbate 80. The formulations have an acidic pH, and enhance the thermal, conformational and colloidal stability of antibodies, including the adalimumab antibody.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: August 13, 2019
    Assignee: Outlook Therapeutics, Inc.
    Inventors: John Cini, Athena Nagi, Maria Taddei
  • Patent number: 10376813
    Abstract: The present invention relates to a method for the determination of chromatography conditions for the separation of a biomolecule from a liquid sample, which method comprises selecting a number of experiments using design of experiments (DoE); performing said experiments with in-line conditioning of orthogonal quality measures; and based on the results from the experiments, determining efficient chromatography conditions for said biomolecule. The invention also relates to a system for performing the method as well as a computer program and an instrument comprising such a computer program.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: August 13, 2019
    Assignee: GE HEALTHCARE BIO-SCIENCES AB
    Inventors: Enrique Napoleon Carredano, Gustav Jose Rodrigo
  • Patent number: 10358498
    Abstract: The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: July 23, 2019
    Assignees: Daiichi Sankyo Europe GmbH, Daiichi Sankyo Company, Limited
    Inventors: Reimar Abraham, Keisuke Fukuchi, Tanja Lange, Johannes Bange, Ichiro Watanabe, Shinko Hayashi, Toshiaki Ohtsuka
  • Patent number: 10351623
    Abstract: The invention relates generally to antagonists of IL-17 isoforms and their uses in diagnosis and therapy, especially for the treatment or prevention of cancers or autoimmune and chronic inflammatory diseases.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 16, 2019
    Assignees: Orega Biotech, Institut National de la Sante et de La Recherche Medicale (INSERM)
    Inventors: Gilles Alberici, Jeremy Bastid, Armand Bensussan, Nathalie Bonnefoy, Jean-Francois Eliaou
  • Patent number: 10330670
    Abstract: Provided are a therapeutic or prophylactic agent for retinopathy of prematurity (ROP) that is suited to the pathogenic mechanism of ROP and a method of testing for ROP. The therapeutic or prophylactic agent for ROP uses at least one substance from the group consisting of inhibitors against tryptase derived from mast cells and/or mast cell stabilizers as an active ingredient. The testing method for ROP includes detecting a marker substance that can be released by degranulation of mast cells in a biological sample originating from a patient and determining the presence or absence of ROP on the basis of the detected amount of the marker.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: June 25, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY, JAPAN INNOVATION THERAPEUTICS, INC.
    Inventors: Hiroshi Matsuda, Akane Tanaka
  • Patent number: 10287345
    Abstract: The present invention relates to antibodies that specifically bind pro-myostatin and/or latent myostatin, and methods and uses thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Scholar Rock, Inc.
    Inventors: Adriana Donovan, Michelle Straub, Stefan Wawersik
  • Patent number: 10273298
    Abstract: The invention provides novel compositions of antibodies based on liquid vehicles selected from semifluorinated alkanes. The use of these vehicles provides for improved stability and shelf-life of antibodies and their derivatives. The compositions are useful for topical administration or for parenteral injection.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: April 30, 2019
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Günther, Dieter Scherer, Anthony Pettigrew, Gesche Graf
  • Patent number: 10259859
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 16, 2019
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
  • Patent number: 10189899
    Abstract: The present disclosure relates to methods for treatment and prevention of disease conditions mediated by T-helper 17 (Th17) and/or T-helper 1 (Th1) T lymphocytes (T cells). In particular, the present disclosure relates to use of anti-CD6 antibody for treatment of disease conditions mediated by auto-reactive Th17 and Th1 T lymphocytes. The methods of the present disclosure further have utility in methods for modulating an immune response by suppressing production of the cytokine IL-23R, thereby decreasing inflammation mediated by Th17 cells.
    Type: Grant
    Filed: July 23, 2014
    Date of Patent: January 29, 2019
    Assignee: BIOCON LIMITED
    Inventors: Pradip Nair, Ramakrishnan Melarkode, Bala S. Manian, Abhijit Barve, Usha Bughani, Jose Enrique Montero Casimiro
  • Patent number: 10111953
    Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 30, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gary Swergold, William J. Sasiela, Robert C. Pordy
  • Patent number: 10081680
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell. Antibodies that are bispecific for SIRP? and a second antigen are termed Bi-specific Macrophage Enhancing (BiME) antibodies and have emergent properties. The subject anti-SIRP? antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRP? antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRP? antibodies.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: September 25, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kipp Andrew Weiskopf, Aaron Michael Ring, Jens-Peter Volkmer, Irving L. Weissman, Nan Guo Ring
  • Patent number: 10059764
    Abstract: The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: August 28, 2018
    Assignee: AnaptysBio, Inc.
    Inventors: Robert A. Horlick, David J. King, Andrew John McKnight
  • Patent number: 10029016
    Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: July 24, 2018
    Assignee: Massachusetts Insitute of Technology
    Inventors: Darrell Irvine, Haipeng Liu
  • Patent number: 10023654
    Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: July 17, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald
  • Patent number: 9975945
    Abstract: The invention relates to a composition comprising immunoglobulins specific to influenza virus and produced through immunization of a producer animal, for use as a medicament for the passive immunization of a human against an infection by an influenza virus, wherein the medicament is administered to the human in at least 1 dose before exposition or risk of exposition to an influenza virus and/or after exposition or risk of exposition to an influenza virus, and wherein the overall amount administered to the human in one or more doses is at least 20 ?g of immunoglobulins per kg body weight. When the composition is for use after exposition or risk of exposition to an influenza virus, it is preferably administered to the human in at least 2 doses after exposition or risk of exposition to an influenza virus.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: May 22, 2018
    Assignee: FABENTECH
    Inventors: Bertrand Lepine, Laurent Vacher, Caroline Durand, Cécile Herbreteau-Delale
  • Patent number: 9956244
    Abstract: A biomarker Hsp90 for predicting an efficacy of a c-Met inhibitor, selecting a subject for application of a c-Met inhibitor, or monitoring an efficacy of a c-Met inhibitor, and a relevant method of using Hsp90.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 1, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ji Min Lee, Bo Gyou Kim, Seung Ja Oh, Kyung Ah Kim, Saet Byoul Lee, Jae Woong Hwang
  • Patent number: 9944704
    Abstract: The present invention discloses antibodies to canine PD-1 that have specific sequences and a high binding affinity for canine PD-1. The invention also discloses the use of the antibodies of the present invention in the treatment of cancer in dogs.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 17, 2018
    Assignee: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
  • Patent number: 9918822
    Abstract: A method of stimulating a renal nerve in a human patient comprising, selecting a span of renal artery in the patient for implantation of a self-expanding stent, the artery having a first internal diameter, an artery wall, and being surrounded by peri-adventitial space through which at least one renal nerve extends; measuring the first internal diameter; selecting a self-expanding stent configured to be capable of expanding to have a second diameter that, in an expanded condition once implanted within the artery, is between 2 mm and 4 mm larger than the first diameter; implanting the stent in the span of the renal artery, whereby the stent eventually expands to the second diameter and thereby passes through the artery wall to become embedded in peri-advential space; and at least partially blocking the renal nerve or modulating a function of the nerve.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: March 20, 2018
    Assignee: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Chad Abunassar, Erik D. Eli, Denis Tauz
  • Patent number: 9914769
    Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: March 13, 2018
    Assignee: Kymab Limited
    Inventor: Jasper Rupert Clube
  • Patent number: 9902986
    Abstract: The present invention provides novel enterobactin-cargo conjugates, such as compounds of Formula (I), and salts thereof, where X is the cargo and may be an antibiotic, a fluorophore, or biotin. The present invention also provides complexes, compositions, kits, and methods that involve the compounds of Formula (I) and are useful in delivering a cargo to a bacterium, treating a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, preventing a bacterial infection, cystic fibrosis, and/or inflammatory bowel disease in a subject, inhibiting the growth of or killing a bacterium, or determining the concentration of a bacterium in a biological sample. In certain embodiments, the bacterium is a Gram-negative bacterium.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: February 27, 2018
    Assignee: Massachusetts Institute of Technology
    Inventors: Elizabeth Marie Nolan, Tengfei Zheng, Phoom Chairatana
  • Patent number: 9803026
    Abstract: A monoclonal antibody that binds to an extracellular domain of human receptor-type protein tyrosine phosphatase ? (human PTPRS), or a fragment including an antigen-binding region thereof.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 31, 2017
    Assignee: SBI Biotech Co., Ltd.
    Inventors: Tomohide Yamazaki, Jing Zhao, Koji Ishida, Yasue Shibata, Minkwon Cho, Mayuki Endo
  • Patent number: 9690975
    Abstract: Techniques are described for determining the quality of a nerve graft by assessing quantitative structural characteristics of the nerve graft. Aspects of the techniques include obtaining an image identifying laminin-containing tissue in the nerve graft; creating a transformed image using a transformation function of an image processing application on the image; using an analysis function of the image processing application, analyzing the transformed image to identify one or more structures in accordance with one or more recognition criteria; and determining one or more structural characteristics of the nerve graft derived from a measurement of the one or more structures.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: June 27, 2017
    Assignee: AXOGEN CORPORATION
    Inventor: Curt Deister
  • Patent number: 9683038
    Abstract: The present invention relates to an IL-1? binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: June 20, 2017
    Assignee: Novartis AG
    Inventors: Tom Thuren, Andrew Zalewski, Michael Shetzline
  • Patent number: 9650429
    Abstract: The present invention provides for a therapeutic cancer treatment using a soluble CD80 fusion protein that binds to PDL1 and inhibits PDL1-PD1 interactions thereby overcoming PDL1-induced immune suppression and restoring T cell activation.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: May 16, 2017
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
    Inventor: Suzanne Ostrand-Rosenberg
  • Patent number: 9637543
    Abstract: Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: May 2, 2017
    Assignees: THE UAB RESEARCH FOUNDATION, BEIJING COTIMES BIOTECH CO., LTD.
    Inventors: Tong Zhou, Donald J. Buchsbaum, Enyun Shen, Xian Chen
  • Patent number: 9598487
    Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: March 21, 2017
    Assignee: ESBATech, an Alcon Biomedical Unit LLC
    Inventors: Leonardo Jose Borras, David Urech
  • Patent number: 9574004
    Abstract: The present invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: February 21, 2017
    Assignees: Sanofi Biotechnology, Regeneron Pharmaceuticals, Inc.
    Inventors: Marius Ardeleanu, Namita A. Gandhi, Neil Graham, Stephanie C. Kirkesseli, Sudeep Kundu, Ross E. Rocklin, Allen Radin, Steven P. Weinstein, Jennifer Davidson Hamilton, Jeffrey Ming